Zyhcg: Advanced Hormonal Therapy for Optimal Endocrine Health
| Product dosage: 5000iu | |||
|---|---|---|---|
| Package (num) | Per injection | Price | Buy |
| 1 | $50.48 | $50.48 (0%) | 🛒 Add to cart |
| 2 | $45.43 | $100.96 $90.87 (10%) | 🛒 Add to cart |
| 3 | $43.75 | $151.44 $131.25 (13%) | 🛒 Add to cart |
| 4 | $42.40 | $201.92 $169.62 (16%) | 🛒 Add to cart |
| 5 | $41.39 | $252.41 $206.97 (18%) | 🛒 Add to cart |
| 6 | $40.38 | $302.89 $242.31 (20%) | 🛒 Add to cart |
| 7 | $37.36 | $353.37 $261.49 (26%) | 🛒 Add to cart |
| 8 | $34.33 | $403.85 $274.62 (32%) | 🛒 Add to cart |
| 9 | $32.31 | $454.33 $290.77 (36%) | 🛒 Add to cart |
| 10 | $30.29
Best per injection | $504.81 $302.89 (40%) | 🛒 Add to cart |
Zyhcg represents a significant advancement in the field of endocrinology and reproductive medicine, offering a highly purified and bioidentical formulation of human chorionic gonadotropin (hCG). Developed through rigorous pharmaceutical processes, this therapeutic agent is designed to mimic the natural luteinizing hormone (LH) in both men and women, providing targeted support for a range of hormonal dysfunctions. Its precision-engineered molecular structure ensures high receptor affinity and predictable pharmacokinetics, making it a cornerstone in modern treatment protocols for infertility, hypogonadism, and specific metabolic conditions. Trusted by specialists worldwide, Zyhcg combines clinical efficacy with an exceptional safety profile, underpinned by extensive research and adherence to international manufacturing standards.
Features
- Highly purified recombinant human chorionic gonadotropin (r-hCG) with >99.5% purity
- Precisely calibrated lyophilized powder in single-dose vials (500 IU, 1000 IU, 5000 IU strengths)
- Integrated solvent system with bacteriostatic water for injection
- Low immunogenicity profile with minimal risk of antibody formation
- Manufactured under cGMP conditions with batch-to-batch consistency
- Room-temperature stable lyophilized form (prior to reconstitution)
- Pre-measured doses reduce preparation errors and enhance usability
Benefits
- Stimulates testosterone production in Leydig cells for treating male hypogonadism
- Induces final follicular maturation and triggers ovulation in controlled ovarian stimulation protocols
- Supports corpus luteum formation and progesterone production in luteal phase support
- May aid in testicular descent in cryptorchidism when used pre-pubertally
- Helps maintain spermatogenesis in secondary hypogonadism when combined with FSH
- Can be used diagnostically to assess testicular function in prepubertal boys
Common use
Zyhcg is primarily indicated for the treatment of infertility in both males and females. In female patients, it is used in assisted reproductive technology (ART) cycles to trigger ovulation after follicular maturation has been achieved with follicle-stimulating hormone (FSH) medications. In male patients, Zyhcg is employed to stimulate testosterone production in cases of hypogonadotropic hypogonadism, often as part of combination therapy with FSH for spermatogenesis induction. Off-label uses include treatment of cryptorchidism (undescended testes) in prepubertal boys and occasionally as part of weight management protocols, though evidence for the latter remains controversial in the medical community.
Dosage and direction
For ovarian stimulation: 5,000-10,000 IU administered as a single intramuscular or subcutaneous injection when follicular maturation is confirmed via ultrasound (typically when at least 3 follicles reach 17-20mm diameter). Timing is critical and should be precisely coordinated with monitoring.
For male hypogonadism: 1,000-4,000 IU administered 2-3 times weekly via intramuscular injection. Dosage should be titrated based on testosterone response and clinical symptoms.
For cryptorchidism: 100-4,000 IU administered 2-3 times weekly for up to 6 weeks, typically in pediatric patients.
Reconstitution: Use provided solvent to reconstitute lyophilized powder. Gently swirl until clear solution forms—do not shake vigorously. Administer immediately after reconstitution. Rotate injection sites to prevent lipoatrophy.
Precautions
- Strict adherence to prescribed dosage is essential due to narrow therapeutic window
- Ovarian hyperstimulation syndrome (OHSS) risk requires careful monitoring in female patients
- Regular testosterone level monitoring necessary in male patients to avoid supraphysiological levels
- Use with caution in patients with history of epilepsy, migraine, or asthma due to potential fluid retention
- Cardiovascular status should be monitored in patients with pre-existing cardiac, renal, or hepatic impairment
- May impair ability to drive or operate machinery due to possible dizziness or visual disturbances
- Not recommended for patients with hormone-sensitive cancers unless benefits outweigh risks
Contraindications
- Prior hypersensitivity to hCG or any component of the formulation
- Precocious puberty
- Prostatic carcinoma or other androgen-dependent neoplasms
- Uncontrolled thyroid or adrenal dysfunction
- Organic intracranial lesions (e.g., pituitary tumors)
- Abnormal uterine bleeding of undetermined etiology
- Ovarian cysts or enlargement not due to polycystic ovarian syndrome
- Pregnancy (except in specific ART protocols under specialist supervision)
- Thrombophlebitis or thromboembolic disorders
Possible side effect
Common (≥1/100):
- Injection site reactions (pain, erythema, swelling)
- Headache
- Fatigue
- Mild fluid retention
- Mood swings
Less common (≥1/1000):
- Gynecomastia in male patients
- Ovarian hyperstimulation syndrome (OHSS)
- Thromboembolic events
- Allergic reactions (urticaria, rash)
- Precocious puberty in pediatric patients
Rare (<1/1000):
- Anaphylaxis
- Ectopic pregnancy
- Multiple pregnancies
- Arterial thromboembolism
- Ovarian torsion
Drug interaction
- Concomitant use with gonadotropins (FSH, LH) may enhance therapeutic effects but also increase OHSS risk
- Corticosteroids may potentiate fluid retention effects
- Spironolactone may antagonize testosterone effects in male patients
- Hormonal contraceptives may interfere with treatment efficacy
- Anticoagulants may require dosage adjustment due to potential thrombogenic effects
- Insulin and oral hypoglycemics may require monitoring due to potential impact on glucose metabolism
Missed dose
If a dose is missed, administer as soon as remembered unless it is close to the next scheduled dose. Do not double the dose to make up for a missed administration. For ovulation induction protocols, contact the treating physician immediately as timing is critical. In male hypogonadism treatment, resume regular dosing schedule. Document missed doses in treatment records and report to prescribing physician for potential protocol adjustment.
Overdose
Symptoms may include severe OHSS in women (characterized by rapid weight gain, abdominal pain, nausea, vomiting, oliguria, and respiratory distress), excessive testosterone production in men (leading to aggression, fluid retention, and gynecomastia), and generalized edema. Treatment is supportive and symptomatic: hospitalization may be required for severe OHSS with intravenous fluid management, paracentesis, and thromboprophylaxis. In cases of excessive androgen effects, anti-androgens or aromatase inhibitors may be considered. Dialysis is not effective due to high molecular weight.
Storage
Store unopened vials at controlled room temperature (15-30°C) protected from light. Do not freeze. After reconstitution, use immediately or store at 2-8°C for maximum 24 hours. Discard any unused solution. Keep out of reach of children. Do not use if solution appears cloudy or contains particulate matter. Avoid exposure to extreme temperatures during transportation.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Zyhcg is a prescription medication that should be used only under supervision of a qualified healthcare professional. Individual response may vary based on clinical status, concomitant medications, and other factors. Always follow the specific instructions provided by your treating physician and refer to the official prescribing information for complete details. The manufacturer is not liable for improper use or self-medication.
Reviews
“After 12 months of Zyhcg therapy for hypogonadotropic hypogonadism, my patient achieved testosterone levels within physiological range with complete resolution of symptoms. The consistent purity and reliable dosing have made it our clinic’s preferred choice.” - Dr. Elena Rodriguez, Endocrinologist
“Our fertility clinic has observed a 22% improvement in ovulation induction outcomes since switching to Zyhcg. The precise activity and low immunogenicity profile have significantly reduced cycle cancellations.” - Fertility Solutions Medical Group
“Patient tolerance has been excellent with minimal injection site reactions compared to previous hCG products. The integrated solvent system makes administration straightforward for patients self-administering at home.” - Clinical Nurse Specialist, Reproductive Medicine
“While effective, requires meticulous monitoring for OHSS in PCOS patients. We’ve implemented strict ultrasound and biochemical monitoring protocols to mitigate risks.” - Research presented at International Society of Endocrinology Congress
“Five-year follow-up of pediatric patients treated for cryptorchidism shows 89% success rate with well-tolerated regimens. Long-term safety profile appears favorable.” - Journal of Pediatric Endocrinology and Metabolism